Dr. Daniel Farray-Berges, M.D.
What this data tells you about Dr. Farray-Berges
Dr. Daniel Farray-Berges is a medical oncology in Weslaco, TX, with 19 years in practice. Based on federal Medicare data, Dr. Farray-Berges performed 34,646 Medicare services across 1,732 unique beneficiaries.
Between the years covered by Open Payments, Dr. Farray-Berges received a total of $2,554 from 25 pharmaceutical and/or device companies across 65 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Farray-Berges is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
Medicare Practice Summary
Medicare Utilization ↗Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Darbepoetin injection (Aranesp) for anemia | 10,440 | $2 | $20 |
| Pembrolizumab injection (Keytruda) | 10,200 | $43 | $137 |
| Anti-nausea injection (fosaprepitant) | 6,900 | $0 | $5 |
| Dexamethasone injection (steroid) | 1,332 | $0 | $1 |
| Blood draw (venipuncture) | 1,015 | $8 | $20 |
| Complete blood count (CBC) with differential | 971 | $8 | $36 |
| Comprehensive metabolic blood panel | 622 | $10 | $64 |
| Anti-nausea injection (Aloxi/palonosetron) | 550 | $1 | $114 |
| Injection, granisetron hydrochloride, 100 mcg | 460 | $0 | $24 |
| Office visit, established patient (30-39 min) | 430 | $94 | $368 |
| Office visit, established patient (20-29 min) | 263 | $57 | $250 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 203 | $22 | $157 |
| Administration of chemotherapy into vein, 1 hour or less | 183 | $98 | $707 |
| Drug injection, under skin or into muscle | 113 | $10 | $96 |
| Injection, zoledronic acid, 1 mg | 89 | $5 | $431 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 78 | $55 | $211 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 67 | $46 | $313 |
| Ferritin level test (iron stores) | 61 | $13 | $60 |
| Iron level test | 60 | $6 | $27 |
| Iron binding capacity test | 60 | $9 | $35 |
| Administration of chemotherapy into vein, each additional hour | 57 | $21 | $161 |
| Administration of additional new drug or substance into vein, 1 hour or less | 54 | $48 | $344 |
| Microscopic examination for white blood cells with manual cell count | 53 | $4 | $22 |
| Complete blood count (CBC), automated | 53 | $6 | $34 |
| Lactate dehydrogenase (enzyme) level | 48 | $6 | $31 |
| PSA test (prostate cancer screening) | 46 | $18 | $94 |
| Injection, diphenhydramine hcl, up to 50 mg | 44 | $1 | $7 |
| New patient office visit (45-59 min) | 35 | $115 | $565 |
| New patient office visit (30-44 min) | 27 | $76 | $372 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 25 | $1,109 | $4,802 |
| Irrigation of implanted venous access drug delivery device | 23 | $18 | $114 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 22 | $26 | $145 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 22 | $90 | $657 |
| Urinalysis with microscopic exam | 17 | $3 | $28 |
| Office visit, established patient, complex (40-54 min) | 12 | $134 | $496 |
| Office visit, established patient (10-19 min) | 11 | $27 | $150 |
Industry Payment Transparency
Open Payments through 2024 ↗Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
Payments by company (2024)
Associated products mentioned in payments ›
Most payments (64%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Farray-Berges is a mixed practice specialist, with above-average Medicare volume (top 26% in TX), and low-engagement industry engagement, with 19 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Farray-Berges experienced with darbepoetin injection (aranesp) for anemia?
Does Dr. Farray-Berges receive payments from pharmaceutical companies?
How do Dr. Farray-Berges's costs compare to other medical oncologys in Weslaco?
What does Data Coverage mean?
Is this data up to date?
Explore related providers
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology